Myomo Inc
NYSE-MKT:MYO
Intrinsic Value
Myomo, Inc. is a medical robotics company that develops, designs, and produces myoelectric orthotics for people with neuromuscular disorders. [ Read More ]
The intrinsic value of one MYO stock under the Base Case scenario is 2.07 USD. Compared to the current market price of 3.41 USD, Myomo Inc is Overvalued by 39%.
Valuation Backtest
Myomo Inc
Run backtest to discover the historical profit from buying and selling MYO stocks based on their intrinsic value.
Analyze the historical link between intrinsic value and market price to make more informed investment decisions.
Fundamental Analysis
US |
Johnson & Johnson
NYSE:JNJ
|
Pharmaceuticals
|
|
US |
Berkshire Hathaway Inc
NYSE:BRK.A
|
Financial Services
|
|
US |
Bank of America Corp
NYSE:BAC
|
Banking
|
|
US |
Mastercard Inc
NYSE:MA
|
Technology
|
|
US |
Abbvie Inc
NYSE:ABBV
|
Biotechnology
|
|
US |
Pfizer Inc
NYSE:PFE
|
Pharmaceuticals
|
|
US |
Palantir Technologies Inc
NYSE:PLTR
|
Technology
|
|
US |
Nike Inc
NYSE:NKE
|
Textiles, Apparel & Luxury Goods
|
|
US |
Visa Inc
NYSE:V
|
Technology
|
|
CN |
Alibaba Group Holding Ltd
NYSE:BABA
|
Retail
|
|
US |
3M Co
NYSE:MMM
|
Industrial Conglomerates
|
|
US |
JPMorgan Chase & Co
NYSE:JPM
|
Banking
|
|
US |
Coca-Cola Co
NYSE:KO
|
Beverages
|
|
US |
Realty Income Corp
NYSE:O
|
Real Estate
|
|
US |
Verizon Communications Inc
NYSE:VZ
|
Telecommunication
|
|
US |
Walt Disney Co
NYSE:DIS
|
Media
|
This note will be permanently deleted.
Balance Sheet Decomposition
Myomo Inc
Current Assets | 13.7m |
Cash & Short-Term Investments | 8.9m |
Receivables | 2.4m |
Other Current Assets | 2.4m |
Non-Current Assets | 930.6k |
PP&E | 839.4k |
Other Non-Current Assets | 91.2k |
Current Liabilities | 5.5m |
Accounts Payable | 1.1m |
Accrued Liabilities | 4.3m |
Other Current Liabilities | 105k |
Non-Current Liabilities | 115.2k |
Other Non-Current Liabilities | 115.2k |
Earnings Waterfall
Myomo Inc
Revenue
|
19.5m
USD
|
Cost of Revenue
|
-6.4m
USD
|
Gross Profit
|
13.2m
USD
|
Operating Expenses
|
-22.6m
USD
|
Operating Income
|
-9.4m
USD
|
Other Expenses
|
110.4k
USD
|
Net Income
|
-9.3m
USD
|
Free Cash Flow Analysis
Myomo Inc
USD | |
Free Cash Flow | USD |
MYO Profitability Score
Profitability Due Diligence
Myomo Inc's profitability score is 29/100. The higher the profitability score, the more profitable the company is.
Score
Myomo Inc's profitability score is 29/100. The higher the profitability score, the more profitable the company is.
MYO Solvency Score
Solvency Due Diligence
Myomo Inc's solvency score is 54/100. The higher the solvency score, the more solvent the company is.
Score
Myomo Inc's solvency score is 54/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
MYO Price Targets Summary
Myomo Inc
According to Wall Street analysts, the average 1-year price target for MYO is 5.76 USD with a low forecast of 2.27 USD and a high forecast of 8.66 USD.
Ownership
MYO Insider Trading
Buy and sell transactions by insiders
Period | Sold | Bought | Net |
---|---|---|---|
3 Months |
|
|
|
6 Months |
|
|
|
9 Months |
|
|
|
12 Months |
|
|
|
Shareholder Return
MYO Price
Myomo Inc
Average Annual Return | -42.46% |
Standard Deviation of Annual Returns | 46.86% |
Max Drawdown | -99% |
Market Capitalization | 92.5m USD |
Shares Outstanding | 28 800 000 |
Percentage of Shares Shorted | 2.3% |
Company Profile
Country
Industry
Market Cap
Dividend Yield
Description
Myomo, Inc. is a medical robotics company that develops, designs, and produces myoelectric orthotics for people with neuromuscular disorders. The company is headquartered in Boston, Massachusetts and currently employs 100 full-time employees. The company went IPO on 2017-06-12. The firm offers functional improvement for those with neuromuscular disorders and upper limb paralysis. The firm develops and markets the MyoPro product line. The MyoPro is a myoelectric-controlled upper limb brace (orthosis). The orthosis is a rigid brace used for the purpose of supporting a patient’s weak or paralyzed arm to enable and help improve functional activities of daily living (ADLs), in the home and community. The MyoPro can enable individuals to self-initiate and control movements of a partially paralyzed or weakened limb using their own muscle signals. The Company’s products are designed to help improve function in adults and adolescents with neuromuscular conditions due to brachial plexus injury, stroke, traumatic brain injury, spinal cord injury and other neurological disorders. The company primarily provides devices directly to patients and bills their insurance companies.
Contact
IPO
Employees
Officers
The intrinsic value of one MYO stock under the Base Case scenario is 2.07 USD.
Compared to the current market price of 3.41 USD, Myomo Inc is Overvalued by 39%.